First treatment for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of small cell lung cancer confirmed by lab testing (biopsy or fluid sample).
- Your cancer is extensive stage (Stage IV) and you have at least one spot that can be measured on scans.
- You have not had any previous cancer treatment (no prior medicines or chemotherapy for small cell lung cancer).
- You can do daily activities fairly well (ECOG 0–1) and are expected to live at least 3 months.
- You must have enough organ function (blood counts and heart/liver/kidney health will be checked).
- You cannot have certain conditions like active brain metastases that are unstable or certain lung inflammation history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
This trial tests different experimental drugs matched to the specific genetic makeup of your small cell lung cancer. The goal is to see if targeting your cancer's particular molecular type can shrink tumors or delay their growth better than standard care.
This trial tests a new combination of immunotherapy (adebrelimab) with chemotherapy and radiation as the first treatment for extensive-stage small-cell lung cancer. It aims to see if this approach can help control the cancer better than standard treatments.
This study tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy followed by targeted chest radiation as the first treatment for extensive-stage small cell lung cancer. The goal is to see if adding radiation after chemo-immunotherapy works better than standard treatment alone.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination is safe and works better than standard care.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.